For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
ORGANIZATION
Reimbursement Prices Kept Unchanged for Over 20% of Drugs: FPMAJ Survey
Over 20% of listed drugs saw their reimbursement prices maintained in the FY2016 price revision in April, higher than the previous revision two years ago, according to a survey conducted by the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ).…
To read the full story
Related Article
- Re-Pricing Rules Need Drastic Overhaul, Possible Abolishment Should Be Discussed for Z2: FPMAJ
June 14, 2016
- FPMAJ Report Warns of Repercussions from Sovaldi Price Slash
June 14, 2016
- FPMAJ Wants to Avoid Narrowing-Down of Premium-Eligible Products: Kamoya
June 13, 2016
- FPMAJ Drug Pricing Affairs Chief Lashes Out at Proposed Out-of-Cycle Re-Pricing
June 13, 2016
ORGANIZATION
- DPP Head, Industry Leaders United towards Stopping Off-Year Price Revisions
November 29, 2024
- PhRMA Wants No Off-Year Price Cuts, Urges Japan Not to Backslide: Chair
November 28, 2024
- JGA to Launch Study Group on Industry Revamp by End of FY2024
November 26, 2024
- Japan Pharmacy Group Demands Abolishing Off-Year Price Revisions
November 22, 2024
- Chuikyo Payer Rep Touts Necessity of FY2025 Off-Year Price Revision
November 19, 2024
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…